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Autoimmune polyglandular syndromes (APSs) include a cluster of autoimmune and nonautoimmune conditions which have
been classified into subtypes. APSs type 1 is characterized by at least two of the following: chronic mucocutaneous candidiasis,
chronic hypoparathyroidism, and autoimmune Addison’s disease (AD). We report the chronological history of a female patient
who presented with features most consistent with APS type 1, along with growth hormone deficiency and juvenile rheumatoid
arthritis (JRA). In terms of her autoimmune diagnoses, she first presented with JRA at three years of age, then hypocalcemia and
hypoparathyroidism at five years of age, type 1 diabetes (DM 1) at age eleven years, adrenal insufficiency at age fourteen years,
recurrent mucocutaneous candidiasis as a teenager, growth hormone deficiency at age fourteen years leading to significant short
stature, primary amenorrhoea, and hypogonadism, and finally alopecia at age twenty-six years. In addition to this, she has suffered
other nonautoimmune medical problems including a Tetralogy of Fallot with a surgical repair at age six years. On review of the
medical literature, we found no other previously reported case with this unique combination of medical problems.
1. Introduction
Autoimmune polyglandular syndromes (APSs) include a clu-
ster of autoimmune and nonautoimmune conditions which
have been classified into four types by Neufeld et al. in 1980
[1, 2]. APS type 1 is characterized by at least two of the fol-
lowing: chronic candidasis, chronic hypoparathyroidism, and
autoimmune Addison’s disease (AD). APS type 2 is defined
by autoimmune AD (must be present) and autoimmune
thyroid disease and/or type 1 diabetes mellitus. APS type 3
involves thyroid autoimmune disease and other autoimmune
diseases (excluding AD, hypoparathyroidism and chronic
candidiasis). Lastly, APS type 4 describes the coexistence of
two or more organ-specific autoimmune diseases and does
not fulfill the criteria of the previous types of APS [1, 2].
Other conditions associated with APS 1 include autoim-
mune thyroid disease, type 1 diabetes (DM 1), hypogo-
nadism, alopecia, vitiligo, keratopathy, autoimmune hepati-
tis, pernicious anemia, and chronic gastritis [3].
APS 1 has been linked to a defect of the autoimmune re-
gulator (AIRE) gene, located on chromosome 21q22.3. This
gene, when defective, downregulates the transcription of sev-
eral tissue-restricted antigens (TRA), resulting in the decre-
ased clonal deletion of autoreactive T cells [4].
We report the chronological history of a female patient
who presented with featuresmost consistent with APS type 1,
along with a variety of other autoimmune and nonautoim-
mune conditions from birth.
2. Case Report
On maternal obstetrical history, the patient’s mother was
G13P10A3. She was forty-one years old at the time of birth
and prenatal complications included per vaginal bleeding at
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five months of gestation. The patient was born by Caesarean
section at thirty-four weeks gestation by dates. APGAR scores
were 6, 8, and 10 at 1, 5, and 10 minutes, respectively. Her
birth weight was 1665 grams. Since birth, her height and
weight have been consistently beneath the fifth percentile. A
karyotype was negative for Turner’s syndrome, and thyroid
function testing was normal.
With respect to her development, the patient demon-
strated significant motor retardation; she was unable to
walk independently until the age of three. There was some
discussion of mild mental retardation initially, but she
completed grade eleven when she was eighteen years old. As a
child and young woman, she has occasionally been described
as elfin and fawn-like.
At three months of age, the patient was diagnosed with
a ventricular septal defect (VSD) with a left- to right- shunt.
She was subsequently diagnosed with a moderate- to- severe
Tetralogy of Fallot and a double-chamber right ventricle by
cardiac catheterization. This was surgically repaired when the
patient was six years old.
At three years of age, she was diagnosed with juvenile
rheumatoid arthritis (JRA), which was treated with non-
steroidal anti-inflammatory drugs (NSAIDs) initially and
later, with intermittent courses of prednisone. Her ESR was
elevated at 31mm/HR. Her antistreptolysin O titer (ASOT),
rheumatoid factor (RF) and antinuclear antibody (ANA)
were negative. Her symptoms decreased in severity over time
although she remains with a 2 cm leg length discrepancy
in her left leg. She has been involved with physiotherapy
since childhood, and they have often remarked on her
hypermobile limbs.
The patient suffered from dental caries from an early age.
She had thirteen extractions, and upon examination, none
of the teeth appeared hypoplastic. She had middle ear issues
as well, requiring bilateral tympanostomy tubes and a left
mastoidectomy for treatment of cholesteatoma. At the age of
five years, she was diagnosed with conductive hearing loss,
requiring the use of hearing aids.
At five years of age, she presented with seizures,
which were initially attributed to hypocalcemia due to
hypoparathyroidism. She was started on vitamin D replace-
ment with cacitriol. Further investigations included an EEG
which demonstrated diffuse encephalopathy and slowing
of cortical rhythms over bilateral hemispheres. An X-ray
brain scan was normal (AP, PA, lateral views × 2). The
patient was diagnosed with a seizure disorder and started
on Phenobarbital. She was subsequently diagnosed with
megaloblastic anemia, presumably secondary to Phenobar-
bital therapy. She was started on folic acid and vitamin B12
supplementation.
Shortly afterwards, the patient was diagnosed with
irritable bowel syndrome and has been on ongoing treatment
throughout her adulthood. She continues to have issues with
constipation.
At eleven years of age, she was diagnosed with DM 1. This
was treated with insulin, and she is currently on a regime of
regular insulin with meals and NPH insulin at bedtime.
After her diagnosis of diabetes, the patient had some
symptoms consistent with adrenal insufficiency; she had a
workup which yielded a normal basal cortisol level and an
appropriate, response following ACTH stimulation. Three
years later, both her basal cortisol (100 nmol/L, range 120
to 600 nmol/L) and ACTH levels were abnormally low, and
the response to an ACTH stimulation test was negligible.
Cortisol levels were 160 nmol/L and 200 nmol/L. There
were concerns regarding primary ACTH deficiency versus
prolonged suppression of ACTH production due to previous
prednisone therapy. She was initially treated with prednisone
and florinef in the morning. This was subsequently changed
to prednisone on a twice daily basis. On prednisone alone,
she had no postural hypotension, decreased episodes of
hypoglycemia overnight, and a normal potassium. Subse-
quent testing, when the patient was thirty-six years old,
demonstrated a detectable ACTH level, suggesting a possible
diagnosis of primary adrenal insufficiency. Ultrasound of the
adrenal glands was normal.
The patient had recurrent episodes of chronic muco-
cutaneous candidiasis and angular stomatitis in childhood
and continued to have episodes intermittently. Skin testing
revealed nonreactivity to multiple fungi, suggesting a deficit
in cell-mediated immunity. She was treated with several
courses of fluconazole with minimal success. Serum gamma
globulin levels were normal for IgG, IgA, and IgM. She has
also had several admissions for pneumonia.
She was investigated for her short stature at the age
of fourteen years, with a bone age of eight years and ten
months. Sleeping growth hormone levels were normal at 32.5
micrograms/L (0.0 to 7.7 micrograms/L), but the response
of growth hormone to arginine stimulation was significantly
depressed. Growth hormone levels were 5.0 micrograms/L,
0.8 micrograms/L, and 1.4 micrograms/L at time zero, thirty
minutes, and sixty minutes after arginine administration.
Her growth hormone level was 0.5 micrograms/L after
twenty minutes of exercise. She was treated with a course
of Fluoxymesterone (Halotestin), and when she was sixteen
years old, she was treated with a trial of growth hormone
injections but with limited success. At the onset of therapy,
her bone age was eight years and six months. When the
patient was nineteen years old, her height was 124.5 cm,
and her bone age was eleven years. Her final height was
130 cm. TSH was normal at 1.68mU/L (0.3 to 3.8mU/L).
There is no family history of short stature or failure to
thrive.
The patient suffered from primary amenorrhea with no
development of secondary sexual characteristics. FSH and
LH levels were high at 95U/L and 46U/L, respectively, and
both responded well to LHRH and TRH stimulation. FSH
and LH were 135U/L and 160U/L at time zero and greater
than 145U/L and 137U/L, respectively, at fifty minutes.
These findings were consistent with primary ovarian failure.
Treatment with hormone therapy was delayed in favour
of initial treatment with growth hormone. She was sub-
sequently started on Estrogen supplement (Premarin) and
Medroxyprogesterone acetate (Provera). The patient chose
to discontinue treatment herself when the results of the
Women’s Health Initiative (WHI) were made public, but re-
started when she was diagnosed with marked osteoporosis
shortly afterwards.
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At the age of nineteen years, the patient was diagnosed
with bilateral cataracts (postcapsular, nuclear, and cortical).
There was no evidence of diabetic retinopathy.
At the age of twenty-six years, she presented with alope-
cia totalis. She has sparing of the eyelashes. She also pre-
sented with dysphagia at this time and was diagnosed
with esophageal webs. She underwent several dilatations for
esophageal stenosis. At this time, she was also diagnosed with
pernicious anemia and started on vitamin B12 supplementa-
tion.
Two years later, at twenty-eight years of age, routine
screening documented elevated creatinine with an elevated
urinemicroalbumin at 134mg/L. She was started on ramipril
for diabetic nephropathy. An ultrasound of the kidneys
showed evidence of nephrocalcinosis. The patient’s kidney
function continued to deteriorate, and at the age of thirty-
five years, she was started on hemodialysis, eventually
switching to peritoneal dialysis. Her kidney function started
improving after a short course of dialysis, and she was able to
discontinue it.
She was seen in the endocrinology clinic at this time, and
her assessment is summarized here.
Her current medications include:
(1) Calcitriol (Rocaltrol) 0.25 micrograms once daily.
(2) Prednisone 5mg once daily in the morning.
(3) Fludrocortisone (Florinef) 0.1mg once daily.
(4) 1 unit of Novolin Toronto Insulin mixed with 7 units
of NPH in a syringe which she takes between 7 a.m.
and 10 a.m. and the same dose, 1 unit of Toronto with
7 units of NPH insulin, at 4:30 p.m..
(5) Premarin 0.625mg from day 1 to day 25 of each
month.
(6) Provera 2.5mg on day 15 to day 25 of each month.
(7) Vitamin B12.
(8) Diflucan as needed.
(9) Nystatin oral suspension as needed.
(10) Colace prn.
2.1. Allergies. The patient has experienced allergic reactions
to Ceftin, Ciprofloxacin, and Bactrium. She presented with a
rash to all of these agents.
2.2. Family History. The patient has six brothers and three
sisters. One brother has adrenal insufficiency, hypoparathy-
roidism, alopecia, and anemia, but he does not have diabetes.
Two sisters and two brothers have rheumatoid arthritis. One
sibling died at the age of three and a half years. There is
no history of consanguinity. Her father died at the age of
seventy-one years due to metastatic cancer with an unknown
primary. Her mother died at the age of seventy-one years of
bowel carcinoma; she also had hypertension. Her maternal
grandmother had Type 1DM.
2.3. Social History. The patient is a life-time nonsmoker and
does not drink any alcohol. She is not working, and she
currently lives with her brother.
2.4. Review of Systems. The patient has gained weight
recently since her most recent esophageal web surgery. Her
bowel movements have been regular. She denies any fatigue,
tiredness, or dizzy spells.
2.5. Physical Examination. Height was 129.8 cm. Weight was
29 kg. Calculated body mass index (BMI) is 17.2. Blood
pressure was 100/60mmHg. On general examination, the
patient is a petite female of short stature in no apparent
distress. She has alopecia totalis and wears a wig. There is no
lid lag or proptosis. On examination of her thyroid, each lobe
measured about 2 cm in vertical dimension. There was some
prominence in the right lobe in the central part, but there
was no obvious nodule. On cardiovascular examination, the
rhythm was regular. Lungs were clear to auscultation. There
was no edema in the lower extremities. Sensation to the 10 g
monofilament was largely intact. There was one patchy area
over the right heel where the monofilament felt different
when compared to the rest of the sole. Dorsalis pedis pulses
were 2 + bilaterally. She has been injecting her insulin mostly
in her arms recently. There were some small bruises in these
areas. The patient does have evidence of past rheumatoid
arthritis involving her hands. She did have a peritoneal
dialysis catheter placed in the right side of her abdomen.
2.6. Recent Investigations. She underwent a combined pitu-
itary stimulation test in the clinical investigation unit (CIU);
this included an insulin hypoglycemia component. Glucose
at baseline was 15.5mmol/L. She received 6 units of insulin,
and her glucose dropped to 2.5mmol/L at 60 minutes
and 1.0mmol/L at 90 minutes. Cortisol did not show any
response. At baseline, it was 17mmol/L, at 30 minutes it
was 21mmol/L, at 60 minutes 19mmol/L, and at 90 minutes
18mmol/L. ACTH levels were 8.0 pmol/L at baseline and
7.7 pmol/L at 60 minutes (normal range 0–10 pmol/L). On
the GnRH test: FSH went from baseline of 11.4U/L to
26.9U/L at 90 minutes. LH went from 3.5U/L at 0 minutes
to 36.6U/L at 90 minutes. TSH rose from 1.84mU/L at
0 minutes to 4.08mU/L at 60 minutes. Her most recent
HbAIC was 7.0%. She did speak to a genetics counsellor
but declined testing for the autoimmune regulator (AIRE)
gene. Her recent laboratory investigations are summarized in
Table 2.
3. Discussion
On review of the medical literature, we found no other
previously reported case with this unique combination of
medical problems. Our patient had evidence of selective pitu-
itary dysfunction with growth hormone deficiency despite
a normally functioning thyroid axis. One other case report
discusses the coincidence of growth hormone deficiency
and APS 1. Franzese et al. describe a female patient who
developed growth hormone insufficiency with delayed bone
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Table 1: Chronologic development of manifestations of APS and
other clinical features.
Diagnosis Age at diagnosis
Low birth weight: 1665 gms 0
VSD 3 months
Juvenile rheumatoid arthritis 3 years
Hypoparathyroidism 5 years
Irritable bowel syndrome 6 years
Repair of Tetralogy of Fallot 6 years
Chronic mucocutaneous candidiasis 8 years?
Type 1 diabetes 11 years
Adrenal Insufficiency 12 years
Growth hormone deficiency 14 years
Ovarian Failure 15 years
Alopecia totalis 26 years
Pernicious anemia 26 years
?
Date is uncertain from the medical record.
Table 2: Selected relevant laboratory parameters.
Laboratory parameter Result Normal range (units)
HbA1C 7.0 (4.0–6.0 gm%)
Parathyroid hormone <3 ng/L 12–65 ng/L
ACTH 8.0 pmol/L 10–65 ng/L
TSH 0.82 0–10 pmol/L
LH 80.2 0.34–5.6mIU/L
FSH 265.9 1.2–12.9 IU/L
Estradiol <73 3.8–8.8 IU/L
age at the age of eight years. She also presented with
hypothyroidism and gonadal failure. She was treated with
recombinant human growth hormone when she was ten
years old and was able to achieve her target height on this
therapy [5]. In her case, the growth hormone insufficiency
was attributed to a partially empty sella found on computed
tomography scanning of the head [5]; however, it does
not explain why her deficit was manifested so late in her
childhood.
The patient in our case report likely developed difficulties
with growth hormone insufficiency early in infancy, as she
has always been and remains beneath the fifth percentile
for height and weight. Her poor response to treatment
with growth hormone may be due to her prolonged
duration of growth hormone insufficiency. In another case
report by Ward et al. [6], autoimmune hypophysitis was
thought to have caused growth hormone deficiency in a
patient with Autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED). This diagnosis was sup-
ported by an appearance of ring enhancement on MRI.
Our patient also had high gonadotropin levels, indicating
that her pituitary gonadotrophs were also intact. The etiology
of hypogonadism in this patient is likely autoimmune. Stud-
ies have shown that ovarian failure in APS type 1 patients
is associated with autoantibodies to several reproductive
tissues, including cells in the adrenal cortex (which secrete
steroid hormone), Graffian follicles, and corpus luteum [7].
Though the patient’s initial workup for adrenal insuffi-
ciency was not clearly diagnostic of primary adrenal insuffi-
ciency, subsequent testing did reveal detectable ACTH levels.
The diagnosis was likely confounded by early treatment with
prednisone for JRA, leading to the suppression of ACTH
production.
At this point, we cannot rule out an autoimmune origin
for our patient’s pituitary deficits, such as a limited lympho-
cytic hypophysitis. This may partly explain the growth hor-
mone insufficiency, in the midst of normal thyroid function.
More unique findings in our case include the presence
of Tetralogy of Fallot and JRA in a patient with APS 1. To
our knowledge, this is the first case report that documents
the coexistence of both of these conditions in APS 1. There
is a case, however, describing the presence of an atrial
septral defect (ASD) in an APS 2 patient [8]. Congenital
heart defects, including septal defects, have been linked to
many genetic syndromes, such as Down’s syndrome [8].
Interestingly, the genetics of DiGeorge syndrome, a deletion
in chromosome 22q11, may be partly responsible for the
different Tetralogy of Fallot phenotypes exhibited in this
syndrome [9]. DiGeorge syndrome also manifests with an
absent thymus and resulting T cell defects and one of the
hypotheses behind APS type 1 involves isolated T cell defects
[10]. The AIRE gene, which is defective in APS type 1, is
mapped to a different chromosome—chromosome 21q22.3
[10]. The increased incidence of autoimmune diseases in
Down syndrome patients is interesting in light of the location
of the AIRE gene on chromosome 21. The addition of
an extra AIRE gene, functional or defective, may have
implications in the presence or severity of the autoimmune
phenotype in a particular individual.
We could find only 2 previous case reports of JRA in an
APS type 1 patient [11]. There is a report of an APS type
II patient with rheumatoid arthritis [12]. In our case, the
patient was RF negative.
The 2 largest case series reported with APS type 1 are
from Finland by the same author possibly including some
common patients: one with 68 cases reported in 1990 did
not mention growth hormone deficiency, short stature, JRA,
or Tetralogy of Fallot as a manifestation of APS 1 [13]. The
other report of 91 cases mentions 5 cases of growth hormone
deficiency but none with JRA [14].
4. Conclusion
This is the case of an APS type 1 patient presenting with
several unusual, and atypical features including growth
hormone deficiency, short stature, JRA and Tetralogy of
Fallot. The inclusion of such cases in the medical literature
allows researchers to link disparate diagnoses from a clinical
viewpoint and to provide thought-provoking hypotheses to
promote further exploration of the underlying mechanisms.
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